Published in J Am Soc Nephrol on May 25, 2005
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol (2010) 2.67
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol (2011) 2.59
Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol (2008) 2.47
Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis (2008) 2.46
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol (2009) 2.26
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int (2012) 1.86
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation (2014) 1.73
Con: Phosphate binders in chronic kidney disease. Nephrol Dial Transplant (2015) 1.72
Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol (2012) 1.66
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol (2010) 1.63
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant (2011) 1.57
Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int (2012) 1.57
Vitamin D: metabolism. Endocrinol Metab Clin North Am (2010) 1.56
Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol (2010) 1.53
FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol (2008) 1.46
Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant (2014) 1.44
FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol (2010) 1.42
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res (2012) 1.41
Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab (2010) 1.38
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 1.37
Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int (2008) 1.36
Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res (2012) 1.28
Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.25
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.24
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int (2009) 1.19
Phosphate and FGF-23. Kidney Int Suppl (2011) 1.19
Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol (2009) 1.16
Overview of the FGF23-Klotho axis. Pediatr Nephrol (2009) 1.15
Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail (2014) 1.15
Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis (2011) 1.15
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol (2011) 1.13
Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol (2013) 1.12
Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant (2008) 1.12
Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol (2007) 1.11
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol (2013) 1.10
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol (2008) 1.07
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol (2013) 1.05
Phosphate and Klotho. Kidney Int Suppl (2011) 1.05
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol (2012) 1.03
The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol (2012) 1.02
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol (2012) 1.02
Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol (2012) 1.02
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol (2014) 1.01
FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol (2012) 1.01
Klotho and the aging process. Korean J Intern Med (2011) 1.01
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2012) 1.01
Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol (2010) 1.00
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int (2016) 1.00
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol (2008) 0.98
Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. J Ren Nutr (2012) 0.97
Serum fibroblast growth factor-23 is associated with incident kidney disease. J Am Soc Nephrol (2014) 0.97
Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens (2008) 0.97
Prevalence and prognostic significance of renal artery calcification in patients with diabetes and proteinuria. Clin J Am Soc Nephrol (2010) 0.97
FGF23 and the parathyroid glands. Pediatr Nephrol (2010) 0.95
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 0.95
A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl (2011) (2013) 0.94
Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients (2013) 0.93
Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol (2011) 0.92
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol (2012) 0.92
Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol (2013) 0.92
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol (2012) 0.92
Mineral (Mal)Adaptation to Kidney Disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol (2015) 0.91
Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant (2014) 0.91
The virtues of vitamin D--but how much is too much? Pediatr Nephrol (2010) 0.90
A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients. BMC Nephrol (2013) 0.90
Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis (2014) 0.89
FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol (2013) 0.89
Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study. Indian J Endocrinol Metab (2011) 0.89
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
"Ghost" publications among applicants to a general surgery residency program. J Am Coll Surg (2008) 3.64
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Scientific writing of novice researchers: what difficulties and encouragements do they encounter? Acad Med (2009) 2.86
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Ollier disease. Orphanet J Rare Dis (2006) 2.11
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial keratoplasty: prospective, randomized, masked clinical trial comparing an injector with forceps for tissue insertion. Am J Ophthalmol (2013) 2.00
Public preferences about secondary uses of electronic health information. JAMA Intern Med (2013) 1.82
A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol (2008) 1.81
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun (2005) 1.78
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int (2005) 1.74
First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol (2003) 1.73
Worse outcomes in patients undergoing urgent surgery for left-sided diverticulitis admitted on weekends vs weekdays: a population-based study of 31 832 patients. Arch Surg (2012) 1.71
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A (2013) 1.68
Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet (2004) 1.68
A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest (2005) 1.68
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab (2008) 1.67
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant (2011) 1.57
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 1.56
Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J (2006) 1.56
GNAS locus and pseudohypoparathyroidism. Horm Res (2005) 1.56
Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol (2011) 1.52
A new quadratic sling for male stress incontinence: retrograde leak point pressure as a measure of urethral resistance. J Urol (2011) 1.51
Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48
Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int (2010) 1.47
Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr (2012) 1.46
Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant (2013) 1.46
Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci U S A (2004) 1.46
Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol (2010) 1.46
Intra- and inter-observer reliability of MRI examination of intervertebral disc abnormalities in patients with cervical myelopathy. Eur J Radiol (2007) 1.44
A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am J Hum Genet (2005) 1.43
Germline mutations affecting Gα11 in hypoparathyroidism. N Engl J Med (2013) 1.43
Patients with Fabry disease on dialysis in the United States. Kidney Int (2002) 1.42
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab (2007) 1.41
Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41
Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit. Mol Endocrinol (2002) 1.40
Observer agreement of spine stenosis on magnetic resonance imaging analysis of patients with cervical spine myelopathy. J Manipulative Physiol Ther (2008) 1.39
Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes (2012) 1.36
Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol (2005) 1.36
Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol (2011) 1.36
Factors enhancing career satisfaction among female emergency physicians. Ann Emerg Med (2008) 1.32